Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have earned an average rating of “Buy” from the eight brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $42.43.
Several brokerages recently issued reports on VERA. Raymond James lifted their price objective on Vera Therapeutics from $57.00 to $68.00 and gave the stock a “strong-buy” rating in a report on Friday, May 10th. JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $65.00 to $62.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th.
View Our Latest Analysis on Vera Therapeutics
Vera Therapeutics Stock Performance
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Analysts expect that Vera Therapeutics will post -2.59 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, CEO Marshall Fordyce sold 14,471 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $39.76, for a total value of $575,366.96. Following the sale, the chief executive officer now directly owns 322,667 shares in the company, valued at $12,829,239.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 21.70% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement Association of Colorado purchased a new stake in shares of Vera Therapeutics during the second quarter worth about $135,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Vera Therapeutics in the 2nd quarter valued at $163,000. Ameritas Investment Partners Inc. lifted its stake in shares of Vera Therapeutics by 20.8% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock worth $172,000 after purchasing an additional 688 shares during the period. Cetera Advisors LLC purchased a new position in shares of Vera Therapeutics during the 1st quarter worth $235,000. Finally, Quarry LP acquired a new stake in shares of Vera Therapeutics during the second quarter worth $235,000. 99.21% of the stock is currently owned by hedge funds and other institutional investors.
Vera Therapeutics Company Profile
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Further Reading
- Five stocks we like better than Vera Therapeutics
- Learn Technical Analysis Skills to Master the Stock Market
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- Want to Profit on the Downtrend? Downtrends, Explained.
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- Best Aerospace Stocks Investing
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.